MX2009010162A - Metodo para tratar dolor mediado por el receptor cb2. - Google Patents

Metodo para tratar dolor mediado por el receptor cb2.

Info

Publication number
MX2009010162A
MX2009010162A MX2009010162A MX2009010162A MX2009010162A MX 2009010162 A MX2009010162 A MX 2009010162A MX 2009010162 A MX2009010162 A MX 2009010162A MX 2009010162 A MX2009010162 A MX 2009010162A MX 2009010162 A MX2009010162 A MX 2009010162A
Authority
MX
Mexico
Prior art keywords
treating
receptor mediated
mediated pain
subject
pain
Prior art date
Application number
MX2009010162A
Other languages
English (en)
Spanish (es)
Inventor
Mark J Macielag
Christopher M Flores
Mingde Xia
Kevin Paul Pavlick
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009010162(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2009010162A publication Critical patent/MX2009010162A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009010162A 2007-03-21 2008-02-27 Metodo para tratar dolor mediado por el receptor cb2. MX2009010162A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89601407P 2007-03-21 2007-03-21
PCT/US2008/055084 WO2008115671A1 (en) 2007-03-21 2008-02-27 Method for treating cb2 receptor mediated pain

Publications (1)

Publication Number Publication Date
MX2009010162A true MX2009010162A (es) 2009-10-12

Family

ID=39766329

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010162A MX2009010162A (es) 2007-03-21 2008-02-27 Metodo para tratar dolor mediado por el receptor cb2.

Country Status (14)

Country Link
US (1) US20080234347A1 (https=)
EP (1) EP2139326A4 (https=)
JP (1) JP2010522181A (https=)
KR (1) KR20090120499A (https=)
CN (1) CN101677556A (https=)
AR (1) AR065800A1 (https=)
AU (1) AU2008229264A1 (https=)
CA (1) CA2681381A1 (https=)
CL (1) CL2008000827A1 (https=)
MX (1) MX2009010162A (https=)
PE (1) PE20090062A1 (https=)
TW (1) TW200901972A (https=)
UY (1) UY30973A1 (https=)
WO (1) WO2008115671A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101787116B1 (ko) * 2009-01-28 2017-10-18 케러 테라퓨틱스, 인코포레이티드 바이시클릭 피라졸로-헤테로사이클
EP3541371A4 (en) * 2017-11-15 2020-07-22 Panag Pharma Inc. METHODS OF TREATING INTERSTITIAL CYSTITIS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698335A4 (en) * 2003-12-26 2007-08-01 Ono Pharmaceutical Co AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR
TW200602324A (en) * 2004-03-24 2006-01-16 Janssen Pharmaceutica Nv Tetrahydro-indazole cannabinoid modulators cross reference to related applications
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
PL1937259T3 (pl) * 2005-09-23 2012-04-30 Janssen Pharmaceutica Nv Heksahydrocykloheptapirazolowe modulatory receptora kanabinoidowego

Also Published As

Publication number Publication date
TW200901972A (en) 2009-01-16
CA2681381A1 (en) 2008-09-25
US20080234347A1 (en) 2008-09-25
CN101677556A (zh) 2010-03-24
JP2010522181A (ja) 2010-07-01
PE20090062A1 (es) 2009-01-26
EP2139326A4 (en) 2011-06-15
WO2008115671A1 (en) 2008-09-25
CL2008000827A1 (es) 2008-09-26
AU2008229264A1 (en) 2008-09-25
UY30973A1 (es) 2008-09-30
EP2139326A1 (en) 2010-01-06
KR20090120499A (ko) 2009-11-24
AR065800A1 (es) 2009-07-01

Similar Documents

Publication Publication Date Title
PH12013500913A1 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
MX2009005649A (es) Tratamiento para mieloma multiple.
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MY158994A (en) Ampk modulators
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
IN2012DN01233A (https=)
TW200744586A (en) Therapeutic compounds
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
IN2012DN00624A (https=)
GEP20166443B (en) Heterocyclic compound and use thereof
WO2009127669A3 (en) Ido inhibitors and therapeutic uses thereof
MA32544B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
NZ601350A (en) Method of treating arthritis
UA107562C2 (uk) Спосіб лікування псоріазу
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
CR10410A (es) Carboxamidas sustituidas.
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.
MX2010003071A (es) Uso de n-fenilamidas de acido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor.
MX2012001449A (es) Inhibidores de cinasas c-jun-n-terminales (jnk).
MX2009010164A (es) Metodo para tratar dolor mediado por el receptor cb2.